2.36
+(+%)
Currency In USD
Address
200 Berkeley Street
Boston, MA 02116
United States of America
Phone
857 702 9600
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
August 05, 2016
| Name | Title | Pay | Year Born |
| Mr. Hyung-Heon Kim | Chief Executive Officer, President & Director | 625,158 | 1975 |
| Mr. Marshall H. Woodworth | Chief Financial Officer | 154,500 | 1958 |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations | 0 | N/A |
| Dr. Mi-Kyung Kim | Chief Scientific Officer | 0 | N/A |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.